Literature DB >> 21386826

Nonredundant roles of IL-10 and TGF-β in suppression of immune responses to hepatic AAV-factor IX gene transfer.

Brad E Hoffman1, Ashley T Martino, Brandon K Sack, Ou Cao, Gongxian Liao, Cox Terhorst, Roland W Herzog.   

Abstract

Hepatic gene transfer using adeno-associated viral (AAV) vectors has been shown to efficiently induce immunological tolerance to a variety of proteins. Regulatory T-cells (Treg) induced by this route suppress humoral and cellular immune responses against the transgene product. In this study, we examined the roles of immune suppressive cytokines interleukin-10 (IL-10) and transforming growth factor-β (TGF-β) in the development of tolerance to human coagulation factor IX (hF.IX). Interestingly, IL-10 deficient C57BL/6 mice receiving gene transfer remained tolerant to hF.IX and generated Treg that suppressed anti-hF.IX formation. Effects of TGF-β blockade were also minor in this strain. In contrast, in C3H/HeJ mice, a strain known to have stronger T-cell responses against hF.IX, IL-10 was specifically required for the suppression of CD8(+) T-cell infiltration of the liver. Furthermore, TGF-β was critical for tipping the balance toward an regulatory immune response. TGF-β was required for CD4(+)CD25(+)FoxP3(+) Treg induction, which was necessary for suppression of effector CD4(+) and CD8(+) T-cell responses as well as antibody formation. These results demonstrate the crucial, nonredundant roles of IL-10 and TGF-β in prevention of immune responses against AAV-F.IX-transduced hepatocytes.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21386826      PMCID: PMC3129563          DOI: 10.1038/mt.2011.33

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  44 in total

1.  Maintenance of the Foxp3-dependent developmental program in mature regulatory T cells requires continued expression of Foxp3.

Authors:  Luke M Williams; Alexander Y Rudensky
Journal:  Nat Immunol       Date:  2007-01-14       Impact factor: 25.606

2.  Induction and role of regulatory CD4+CD25+ T cells in tolerance to the transgene product following hepatic in vivo gene transfer.

Authors:  Ou Cao; Eric Dobrzynski; Lixin Wang; Sushrusha Nayak; Bethany Mingle; Cox Terhorst; Roland W Herzog
Journal:  Blood       Date:  2007-04-16       Impact factor: 22.113

3.  Muscle as a target for supplementary factor IX gene transfer.

Authors:  Brad E Hoffman; Eric Dobrzynski; Lixin Wang; Lauren Hirao; Federico Mingozzi; Ou Cao; Roland W Herzog
Journal:  Hum Gene Ther       Date:  2007-07       Impact factor: 5.695

4.  Long-term correction of inhibitor-prone hemophilia B dogs treated with liver-directed AAV2-mediated factor IX gene therapy.

Authors:  Glenn P Niemeyer; Roland W Herzog; Jane Mount; Valder R Arruda; D Michael Tillson; John Hathcock; Frederik W van Ginkel; Katherine A High; Clinton D Lothrop
Journal:  Blood       Date:  2008-10-28       Impact factor: 22.113

5.  IL-10 and TGF-beta redundantly protect against severe liver injury and mortality during acute schistosomiasis.

Authors:  De'Broski R Herbert; Tatyana Orekov; Charles Perkins; Fred D Finkelman
Journal:  J Immunol       Date:  2008-11-15       Impact factor: 5.422

6.  Prevention of cytotoxic T lymphocyte responses to factor IX-expressing hepatocytes by gene transfer-induced regulatory T cells.

Authors:  Eric Dobrzynski; Julie C Fitzgerald; Ou Cao; Federico Mingozzi; Lixin Wang; Roland W Herzog
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-10       Impact factor: 11.205

7.  Coexpression of TGF-beta1 and IL-10 enables regulatory T cells to completely suppress airway hyperreactivity.

Authors:  Katrin Presser; Dorothee Schwinge; Michael Wegmann; Samuel Huber; Steffen Schmitt; Alexander Quaas; Joachim H Maxeiner; Susetta Finotto; Ansgar W Lohse; Manfred Blessing; Christoph Schramm
Journal:  J Immunol       Date:  2008-12-01       Impact factor: 5.422

8.  Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response.

Authors:  Catherine S Manno; Glenn F Pierce; Valder R Arruda; Bertil Glader; Margaret Ragni; John J Rasko; John Rasko; Margareth C Ozelo; Keith Hoots; Philip Blatt; Barbara Konkle; Michael Dake; Robin Kaye; Mahmood Razavi; Albert Zajko; James Zehnder; Pradip K Rustagi; Hiroyuki Nakai; Amy Chew; Debra Leonard; J Fraser Wright; Ruth R Lessard; Jürg M Sommer; Michael Tigges; Denise Sabatino; Alvin Luk; Haiyan Jiang; Federico Mingozzi; Linda Couto; Hildegund C Ertl; Katherine A High; Mark A Kay
Journal:  Nat Med       Date:  2006-02-12       Impact factor: 53.440

9.  Regulatory T cells expressing interleukin 10 develop from Foxp3+ and Foxp3- precursor cells in the absence of interleukin 10.

Authors:  Craig L Maynard; Laurie E Harrington; Karen M Janowski; James R Oliver; Carlene L Zindl; Alexander Y Rudensky; Casey T Weaver
Journal:  Nat Immunol       Date:  2007-08-12       Impact factor: 25.606

10.  IL-4 inhibits TGF-beta-induced Foxp3+ T cells and, together with TGF-beta, generates IL-9+ IL-10+ Foxp3(-) effector T cells.

Authors:  Valérie Dardalhon; Amit Awasthi; Hyoung Kwon; George Galileos; Wenda Gao; Raymond A Sobel; Meike Mitsdoerffer; Terry B Strom; Wassim Elyaman; I-Cheng Ho; Samia Khoury; Mohamed Oukka; Vijay K Kuchroo
Journal:  Nat Immunol       Date:  2008-11-09       Impact factor: 25.606

View more
  41 in total

1.  Cytokine-conditioned dendritic cells induce humoral tolerance to protein therapy in mice.

Authors:  Gautam Sule; Masataka Suzuki; Kilian Guse; Racel Cela; John R Rodgers; Brendan Lee
Journal:  Hum Gene Ther       Date:  2012-05-11       Impact factor: 5.695

2.  The role of apoptosis in immune hyporesponsiveness following AAV8 liver gene transfer.

Authors:  Susan M Faust; Peter Bell; Yanqing Zhu; Julio Sanmiguel; James M Wilson
Journal:  Mol Ther       Date:  2013-10-15       Impact factor: 11.454

Review 3.  Pompe disease gene therapy.

Authors:  Barry J Byrne; Darin J Falk; Christina A Pacak; Sushrusha Nayak; Roland W Herzog; Melissa E Elder; Shelley W Collins; Thomas J Conlon; Nathalie Clement; Brian D Cleaver; Denise A Cloutier; Stacy L Porvasnik; Saleem Islam; Mai K Elmallah; Anatole Martin; Barbara K Smith; David D Fuller; Lee Ann Lawson; Cathryn S Mah
Journal:  Hum Mol Genet       Date:  2011-04-25       Impact factor: 6.150

4.  Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells.

Authors:  Ashley T Martino; Etiena Basner-Tschakarjan; David M Markusic; Jonathan D Finn; Christian Hinderer; Shangzhen Zhou; David A Ostrov; Arun Srivastava; Hildegund C J Ertl; Cox Terhorst; Katherine A High; Federico Mingozzi; Roland W Herzog
Journal:  Blood       Date:  2013-01-16       Impact factor: 22.113

Review 5.  Liver induced transgene tolerance with AAV vectors.

Authors:  Geoffrey D Keeler; David M Markusic; Brad E Hoffman
Journal:  Cell Immunol       Date:  2017-12-05       Impact factor: 4.868

6.  The Balance between CD8+ T Cell-Mediated Clearance of AAV-Encoded Antigen in the Liver and Tolerance Is Dependent on the Vector Dose.

Authors:  Sandeep R P Kumar; Brad E Hoffman; Cox Terhorst; Ype P de Jong; Roland W Herzog
Journal:  Mol Ther       Date:  2017-03-09       Impact factor: 11.454

7.  The threefold protrusions of adeno-associated virus type 8 are involved in cell surface targeting as well as postattachment processing.

Authors:  Christina Raupp; Matthias Naumer; Oliver J Müller; Brittney L Gurda; Mavis Agbandje-McKenna; Jürgen A Kleinschmidt
Journal:  J Virol       Date:  2012-06-20       Impact factor: 5.103

Review 8.  Pompe disease gene therapy: neural manifestations require consideration of CNS directed therapy.

Authors:  Barry J Byrne; David D Fuller; Barbara K Smith; Nathalie Clement; Kirsten Coleman; Brian Cleaver; Lauren Vaught; Darin J Falk; Angela McCall; Manuela Corti
Journal:  Ann Transl Med       Date:  2019-07

9.  Engineered antigen-specific human regulatory T cells: immunosuppression of FVIII-specific T- and B-cell responses.

Authors:  Yong Chan Kim; Ai-Hong Zhang; Yan Su; Sadiye Amcaoglu Rieder; Robert J Rossi; Ruth A Ettinger; Kathleen P Pratt; Ethan M Shevach; David W Scott
Journal:  Blood       Date:  2014-12-10       Impact factor: 22.113

10.  Portal vein delivery of viral vectors for gene therapy for hemophilia.

Authors:  Alexandra Sherman; Alexander Schlachterman; Mario Cooper; Elizabeth P Merricks; Robin A Raymer; Dwight A Bellinger; Roland W Herzog; Timothy C Nichols
Journal:  Methods Mol Biol       Date:  2014
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.